Physician profile

Samuel Sestito

Pittsburgh, PA

NPI 1083277131

$719.12

in general payments reported to CMS, 2019-2025

6 companies · $360 in 2025

The $360 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$520.18
Education$198.94

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $300.66 2024-2025 Calquence
Abbvie INC. $138.61 2025
Lilly USA, LLC $124.70 2024-2025 Verzenio, Jaypirca
Takeda Pharmaceuticals U.S.A., INC. $99.99 2023
Boehringer Ingelheim Pharmaceuticals, INC. $28.84 2024 Gilotrif
Janssen Biotech, INC. $26.32 2024 Erleada

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Samuel Sestito

$719.12

in general payments reported 2019-2025

Years
2023-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $360 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/11562525/samuel-sestito

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.